PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

The first patient has been treated in a phase 1/2 clinical ... melanoma. PD-L1 is a cell surface receptor expressed on both tumour and regulatory immune cells and functions as a checkpoint to ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...

ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...

A new ‘storehouse’ function ascribed to the spleen ... Elovl1-depleted T cells gain increased fitness and synergize with anti-PD-1 therapy to enhance antitumour responses.